Abivax (AAVXF) Interest Expenses (2024 - 2025)
Abivax (AAVXF) posted Interest Expenses of $53.1 billion for Q4 2025, up 67981.62% on a QoQ basis from -$78.3 million in Q3 2025, and up 250.5% year-over-year from $15.2 billion in Q4 2024.
Powered by 
Analysis
Abivax (AAVXF) Interest Expenses (2024 - 2025) Analysis & Trends
Abivax has reported Interest Expenses for 2 years, with the latest figure at $53.1 billion in Q4 2025.
- On a quarterly basis, Interest Expenses rose 250.5% year-over-year to $53.1 billion in Q4 2025; TTM through Mar 2026 was $53.1 billion, a 250.11% increase from a year earlier, with the FY2025 full-year figure at $53.1 billion, up 250.04% from the prior year.
- Interest Expenses was $53.1 billion for Q4 2025 at Abivax, up from -$78.3 million in the prior quarter.
- The five-year high for Interest Expenses was $53.1 billion in Q4 2025, with the low at -$78.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | - |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 53.14 Bn |
| Sep 30, 2025 | -78.28 Mn |
| Jun 30, 2025 | -405,241.57 |
| Mar 31, 2025 | -1.48 Mn |
| Dec 31, 2024 | 15.16 Bn |
| Sep 30, 2024 | -1.96 Mn |
| Jun 30, 2024 | -2.30 Mn |
| Mar 31, 2024 | -1.29 Mn |